Overall Survival & Tumor response rate in Metastatic Breast cancer Chemotherapy

To compare Taxanes, antitumor antibiotics and platinum containing chemotherapy regimens in the management of metastatic breast cancer in terms of overall survival, objective response rate and time to progression.Cochrane breast cancer group specialized register; cochrane central register of controlled trials (central), medline, embase, cinahl and who international clinical registry platform were searched using the appropriate search strategy selection criteria. Response rates were analysed as dichotomous variables. 35 trials were included with sample size of 16272 patients with Advanced Metastatic Breast Cancer treated with either Antitumor Antibiotics or Platinum Regimens or Taxanes. The observed overall survival derived for a sample size of 2710 exposed to chemotherapy where as a comparator group of 2591 exposed other therapies. The overall risk ratio was 0.98(M-H, fixed, 95% CI; 0.95 to 1.01).Tumor Response Rate derived for a sample size of 3037 exposed to chemotherapy in comparison to the comparator group of 2951 exposed to other therapies. This study confirms several benefits of chemotherapy especially taxanes, antitumor antibiotics and platinum regimen in metastatic breast cancer, but the selection of drug therapy must be based upon the presentation of the case. Key words: Breast Cancer, Metastasis, Overall Survival, Tumor Response Rate.